Published in Am J Respir Crit Care Med on March 22, 2007
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease. Am J Respir Crit Care Med (2012) 1.63
Reduced fitness and abnormal cardiopulmonary responses to maximal exercise testing in children and young adults with sickle cell anemia. Physiol Rep (2015) 1.44
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med (2012) 1.35
Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol (2008) 1.34
Increased pulmonary pressures and myocardial wall stress in children with severe malaria. J Infect Dis (2010) 1.33
Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol (2012) 1.31
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol (2010) 1.25
Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood (2008) 1.18
Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica (2010) 1.16
Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med (2013) 1.16
The impact of recurrent acute chest syndrome on the lung function of young adults with sickle cell disease. Lung (2010) 1.07
Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med (2008) 1.07
Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease. Microvasc Res (2012) 1.06
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol (2008) 1.04
Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol (2014) 1.03
Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest (2010) 1.03
Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One (2014) 1.00
NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. Br J Haematol (2011) 0.96
Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med (2013) 0.95
Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis (2013) 0.93
Longitudinal analysis of pulmonary function in adults with sickle cell disease. Am J Hematol (2008) 0.91
Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease. Br J Haematol (2013) 0.87
Hematological and hemorheological determinants of the six-minute walk test performance in children with sickle cell anemia. PLoS One (2013) 0.86
Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension. Pulm Circ (2013) 0.85
Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. Eur J Haematol (2013) 0.84
Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung (2008) 0.84
The role of fibrocytes in sickle cell lung disease. PLoS One (2012) 0.84
Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Proc Natl Acad Sci U S A (2016) 0.83
Abnormalities in cardiac structure and function in adults with sickle cell disease are not associated with pulmonary hypertension. J Am Soc Echocardiogr (2011) 0.83
Clinical and electrocardiographic evaluation of sickle-cell anaemia patients with pulmonary hypertension. ISRN Hematol (2012) 0.83
Lung function and six-minute walk test performance in individuals with sickle cell disease. Braz J Phys Ther (2014) 0.82
Computed tomography correlates with cardiopulmonary hemodynamics in pulmonary hypertension in adults with sickle cell disease. Pulm Circ (2014) 0.81
Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension. Med Phys (2010) 0.80
Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood (2016) 0.80
Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. Haematologica (2012) 0.79
Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest (2017) 0.78
TRV: a physiological biomarker in sickle cell disease. Pediatr Blood Cancer (2011) 0.78
Uric Acid as a potential biomarker of pulmonary arterial hypertension in patients with sickle cell disease. Indian J Hematol Blood Transfus (2011) 0.77
Sickle cell disease-associated pulmonary hypertension: a coat of many colors. Am J Respir Crit Care Med (2007) 0.77
The PhysioFlow thoracic impedancemeter is not valid for the measurements of cardiac hemodynamic parameters in chronic anemic patients. PLoS One (2013) 0.75
CT and image processing non-invasive indicators of sickle cell secondary pulmonary hypertension. Conf Proc IEEE Eng Med Biol Soc (2008) 0.75
Pediatric Exercise Testing: Value and Implications of Peak Oxygen Uptake. Children (Basel) (2017) 0.75
Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease. Cardiol Clin (2016) 0.75
Pulmonary function in children and adolescents with sickle cell disease: have we paid proper attention to this problem? J Bras Pneumol (2017) 0.75
A novel expression of exercise induced pulmonary hypertension in human immunodeficiency virus patients: a pilot study. Open Cardiovasc Med J (2012) 0.75
Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension. Ethn Dis (2016) 0.75
Venous Thromboembolism in Children with Cancer and Blood Disorders. Front Pediatr (2017) 0.75
Pulmonary hypertension in Nigerian adults with sickle cell anemia. Vasc Health Risk Manag (2017) 0.75
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia. Ann Thorac Med (2014) 0.75
Relationship between ventilation heterogeneity and exercise intolerance in adults with sickle cell anemia. Braz J Med Biol Res (2017) 0.75
Cardiorespiratory pathogenesis of sickle cell disease in a mouse model. Sci Rep (2017) 0.75
Physical activity level and performance in the six-minute walk test of children and adolescents with sickle cell anemia. Rev Bras Hematol Hemoter (2017) 0.75
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA (2005) 6.49
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med (1992) 6.40
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update. Am J Respir Crit Care Med (1995) 3.95
Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol (1985) 3.50
Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol (2006) 2.83
Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol (2007) 2.76
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 2.64
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood (2002) 2.60
Predicted values for clinical exercise testing. Am Rev Respir Dis (1984) 2.58
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Causes of death in sickle cell disease: an autopsy study. Br J Haematol (2003) 1.96
ATS statement on six-minute walk test. Am J Respir Crit Care Med (2003) 1.84
Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med (2003) 1.78
Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol (2002) 1.73
Cardiac involvement in thalassemia intermedia: a multicenter study. Blood (2001) 1.67
Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol (2002) 1.45
HEMODYNAMIC EFFECTS OF CHRONIC SEVERE ANEMIA. Circulation (1963) 1.36
Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol (2005) 1.36
Hemodynamic studies in sickle cell anemia. Circulation (1954) 1.35
Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med (2001) 1.31
Pulmonary hypertension in sickle cell disease. N Engl J Med (2004) 1.15
Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol (2003) 1.06
Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. Am J Respir Crit Care Med (2001) 1.06
Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study. Hepatogastroenterology (2003) 1.06
Successful pulmonary thromboendarterectomy in two patients with sickle cell disease. Am J Respir Crit Care Med (1998) 0.98
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 0.90
Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients with glucose-6-phosphate dehydrogenase deficiency. Ann Thorac Surg (2003) 0.90
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 0.89
Haemolysis during cardiopulmonary bypass: how to reduce the free haemoglobin by managing the suctioned blood separately. Perfusion (2001) 0.89
A clinical evaluation of platelet function, haemolysis and oxygen transfer during cardiopulmonary bypass comparing the Quantum HF-6700 to the HF-5700 hollow fibre membrane oxygenator. Perfusion (2000) 0.86
Hemolytic characteristics of a pivot bearing supported Gyro centrifugal pump (C1E3) simulating various clinical applications. Artif Organs (1996) 0.85
Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest (1996) 0.84
Mitral valve replacement with ball and tilting disc valve prosthesis. A clinical and haemodynamic study. Scand J Thorac Cardiovasc Surg (1976) 0.80
Systemic surgical shunts and splenomegaly as causes of haemolysis in portal hypertension in mansonic schistosomiasis. Evaluation through serum levels of haptoglobin, hemopexin and bilirubins. J Hepatol (1986) 0.80
[Hemolytic anemia due to aortic valve regurgitation after mitral valve replacement]. Kyobu Geka (2003) 0.80
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med (2003) 8.95
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med (2002) 7.59
The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov (2008) 7.58
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res (2009) 6.83
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA (2005) 6.49
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Sickle-cell disease. Lancet (2010) 5.64
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med (2008) 5.34
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med (2013) 4.98
Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med (2003) 4.98
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation (2006) 4.69
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med (2008) 4.33
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest (2005) 4.14
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med (2002) 3.91
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation (2013) 3.84
Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med (2007) 3.29
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Tumor-induced osteomalacia. Endocr Relat Cancer (2011) 3.13
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med (2008) 3.13
Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest (2005) 3.08
Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med (2008) 3.04
Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res (2007) 2.91
Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation (2013) 2.82
Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2004) 2.79
Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol (2007) 2.76
Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood (2005) 2.76
Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest (2005) 2.75
Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol (2006) 2.75
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis (2003) 2.73
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest (2007) 2.67
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest (2006) 2.60
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol (2007) 2.60
Chronic thromboembolic pulmonary hypertension. Circulation (2006) 2.58
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA (2008) 2.55
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol (2010) 2.55
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2009) 2.51
Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA (2005) 2.47
Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation (2007) 2.46
A network model to predict the risk of death in sickle cell disease. Blood (2007) 2.39
The reaction between nitrite and deoxyhemoglobin. Reassessment of reaction kinetics and stoichiometry. J Biol Chem (2005) 2.34
Pulmonary arterial hypertension. J Am Coll Cardiol (2008) 2.34
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood (2007) 2.30
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Catalytic generation of N2O3 by the concerted nitrite reductase and anhydrase activity of hemoglobin. Nat Chem Biol (2007) 2.30
Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol (2009) 2.29
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med (2015) 2.23
Mortality increases after massive exchange transfusion with older stored blood in canines with experimental pneumonia. Blood (2012) 2.22
NO contest: nitrite versus S-nitroso-hemoglobin. Circ Res (2004) 2.21
Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica (2009) 2.20
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2008) 2.17
Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev (2009) 2.15
Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation (2008) 2.14
The relationship between pulmonary emphysema and kidney function in smokers. Chest (2012) 2.13
Technology preview: X-ray fused with magnetic resonance during invasive cardiovascular procedures. Catheter Cardiovasc Interv (2007) 2.12
Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med (2004) 2.09
Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood (2005) 2.08
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab (2003) 2.08
Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood (2004) 2.06
Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol (2002) 2.06
Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 2.06
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
The right ventricle in pulmonary hypertension. Coron Artery Dis (2005) 2.03
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest (2003) 2.00
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab (2011) 1.98